In conclusion, SGR-EA has an obvious anti-breast cancer effect, specifically by inhibiting the activation of the HIF-1 signaling pathway of tumor-associated macrophages, reversing the M2 polarization of tumor-associated macrophages, and regulating the tumor immune microenvironment. The gene discussed is HIF1A; the disease is breast carcinoma.